Prevention of hepatitis B reactivation with lamivudine in hepatitis B virus carriers with hematologic malignancies treated with chemotherapy

 
This item is provided by the institution :

Repository :
Annals of Gastroenterology
see the original item page
in the repository's web site and access all digital files if the item*
share




2007 (EN)
Prevention of hepatitis B reactivation with lamivudine in hepatitis B virus carriers with hematologic malignancies treated with chemotherapy (EN)

K. Tziomalos, V. Perifanis, Olga Giouleme, Sofia Vakalopoulou, Th. Vassiliadis, Vassilia Garipidou,

SUMMARY Background: Administration of immunosuppressive treatment in hepatitis B virus carriers with malignancies is associated with the risk of hepatitis B reactivation. This complication is more frequent in patients with hematologic malignancies because administration of corticosteroids, the mainstay of treatment of these patients, is an independent risk factor for hepatitis B reactivation. When lamivudine is given prior to chemotherapy, it prevents the viral replication during the immunosuppression period; therefore, it might reduce the risk of hepatitis B exacerbation. Aim: To assess the efficacy of prophylactic administration of lamivudine in this setting. Methodology: Ten hepatitis B virus carriers with hematologic malignancies were included in the study; seven were HBsAg positive and three had isolated antiHBc and detectable HBV-DNA levels. Nine patients were given corticosteroids after the administration of lamivudine. Lamivudine was given per os at a dose of 100 mg once daily. In four patients who had not been previously treated with chemotherapy, lamivudine was started 19 days (median) (range, 0-35 days) prior to the onset of chemotherapy. The administration of lamivudine has not been stopped since in any of our patients. Results: After a median follow-up of 15 months (range 6-38 months) no hepatitis B reactivation was observed. HBV-DNA levels were decreased in all six patients who had detectable HBVDNA at baseline. Lamivudine was well tolerated. Chemotherapy regimens were administered as planned and their effectiveness was not compromised by lamivudine. Conclusion: Prophylactic administration of lamivudine is a safe and effective method to reduce the frequency of hepatitis B reactivation in hepatitis B virus carriers with hematologic malignancies, who are being treated with chemotherapy. Key words: chemotherapy, hematologic malignancies, hepatitis B reactivation, lamivudine (EN)

info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion

Ελληνική Γαστροεντερολογική Εταιρία (EL)
Hellenic Society of Gastroenterology (EN)

2007-03-19


Hellenic Society of Gastroenterology (EN)

1792-7463
1108-7471
Annals of Gastroenterology; Volume 17, No 3 (2004) (EN)



*Institutions are responsible for keeping their URLs functional (digital file, item page in repository site)